PMID- 25932941
OWN - NLM
STAT- MEDLINE
DCOM- 20160126
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 5
DP  - 2015
TI  - Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV 
      Coinfected Patients Treated with Pegylated Interferon and Ribavirin.
PG  - e0125604
LID - 10.1371/journal.pone.0125604 [doi]
LID - e0125604
AB  - Association between hepatitis C virus (HCV) quasispecies and treatment outcome 
      among patients with chronic hepatitis C has been the subject of many studies. 
      However, these studies focused mainly on viral variable regions (E1 and E2) and 
      usually did not include human immunodeficiency virus (HIV)-positive patients. The 
      aim of the present study was to analyze heterogeneity of the 5' untranslated 
      region (5'UTR) in HCV/HIV coinfected patients treated with interferon and 
      ribavirin. The HCV 5'UTR was amplified from serum and peripheral blood 
      mononuclear cells (PBMC) samples in 37 HCV/HIV coinfected patients treated for 
      chronic hepatitis C. Samples were collected right before treatment, and at 2, 4, 
      6, 8, 12, 20, 24, 36, 44, 48, 60, and 72 weeks. Heterogeneity of the 5'UTR was 
      analyzed by single strand conformational polymorphism (SSCP), cloning and 
      sequencing. Sustained virological response (SVR) was achieved in 46% of analyzed 
      HCV/HIV co-infected patients. Stable SSCP band pattern was observed in 22 
      patients (62.9%) and SVR rate among these patients was 23%. Decline in the number 
      of bands and/or shift in band positions were found in 6 patients (17.1%), 5 (83%) 
      of whom achieved SVR (p=0.009). A novel viral genotype was identified in all but 
      one of these patients. In 5 of these 6 patients a new genotype was dominant. 
      5'UTR heterogeneity may correlate with interferon and ribavirin treatment 
      outcome. In the analyzed group of HCV/HIV coinfected patients, viral quasispecies 
      stability during treatment favored viral persistence, whereas decrease in the 
      number of variants and/or emergence of new variants was associated with SVR. 
      Among injection drug users (IDU) patients, a new genotype may become dominant 
      during treatment, probably due to the presence of mixed infections with various 
      strains, which have different susceptibility to treatment.
FAU - Bukowska-Osko, Iwona
AU  - Bukowska-Osko I
AD  - Department of Immunopathology, Warsaw Medical University, Warsaw, Poland.
FAU - Pawelczyk, Agnieszka
AU  - Pawelczyk A
AD  - Department of Immunopathology, Warsaw Medical University, Warsaw, Poland.
FAU - Perlejewski, Karol
AU  - Perlejewski K
AD  - Department of Immunopathology, Warsaw Medical University, Warsaw, Poland.
FAU - Kubisa, Natalia
AU  - Kubisa N
AD  - Department of Immunopathology, Warsaw Medical University, Warsaw, Poland.
FAU - Caraballo Cortes, Kamila
AU  - Caraballo Cortes K
AD  - Department of Immunopathology, Warsaw Medical University, Warsaw, Poland.
FAU - Rosinska, Magdalena
AU  - Rosinska M
AD  - Department of Epidemiology, National Institute of Hygiene, Warsaw, Poland.
FAU - Ploski, Rafal
AU  - Ploski R
AD  - Department of the Medical Genetics, Warsaw Medical University, Warsaw, Poland.
FAU - Fic, Maria
AU  - Fic M
AD  - Department of Immunopathology, Warsaw Medical University, Warsaw, Poland.
FAU - Kazmierczak, Justyna
AU  - Kazmierczak J
AD  - Department of Immunopathology, Warsaw Medical University, Warsaw, Poland.
FAU - Popiel, Marta
AU  - Popiel M
AD  - Department of Immunopathology, Warsaw Medical University, Warsaw, Poland.
FAU - Zabek, Piotr
AU  - Zabek P
AD  - Hospital of Infectious Diseases, Warsaw, Poland.
FAU - Horban, Andrzej
AU  - Horban A
AD  - Hospital of Infectious Diseases, Warsaw, Poland.
FAU - Radkowski, Marek
AU  - Radkowski M
AD  - Department of Immunopathology, Warsaw Medical University, Warsaw, Poland.
FAU - Laskus, Tomasz
AU  - Laskus T
AD  - Department of Immunopathology, Warsaw Medical University, Warsaw, Poland.
LA  - eng
PT  - Journal Article
DEP - 20150501
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (5' Untranslated Regions)
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon-alpha)
RN  - 0 (Interleukins)
RN  - 49717AWG6K (Ribavirin)
SB  - IM
MH  - 5' Untranslated Regions/*genetics
MH  - Adult
MH  - Antiviral Agents/pharmacology/therapeutic use
MH  - Base Sequence
MH  - Coinfection/*drug therapy/*virology
MH  - Female
MH  - *Genetic Variation
MH  - HIV/drug effects/*genetics
MH  - Hepacivirus/drug effects/*genetics
MH  - Humans
MH  - Interferon-alpha/pharmacology/*therapeutic use
MH  - Interleukins/genetics
MH  - Male
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Polymorphism, Single-Stranded Conformational/genetics
MH  - Ribavirin/pharmacology/*therapeutic use
MH  - Sequence Alignment
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC4416933
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/05/02 06:00
MHDA- 2016/01/27 06:00
PMCR- 2015/05/01
CRDT- 2015/05/02 06:00
PHST- 2014/11/04 00:00 [received]
PHST- 2015/03/24 00:00 [accepted]
PHST- 2015/05/02 06:00 [entrez]
PHST- 2015/05/02 06:00 [pubmed]
PHST- 2016/01/27 06:00 [medline]
PHST- 2015/05/01 00:00 [pmc-release]
AID - PONE-D-14-49592 [pii]
AID - 10.1371/journal.pone.0125604 [doi]
PST - epublish
SO  - PLoS One. 2015 May 1;10(5):e0125604. doi: 10.1371/journal.pone.0125604. 
      eCollection 2015.